ACVRL1 and acute myeloid leukemia: In vitro and in vivo studies have shown that HHT and FLT3 inhibitors function in conjunction.[72] HHT is an essential partner in the therapy of FLT3-ITD AML along with FLT3 inhibition (Fig. 3).